Hayashi H, Fujii T, Fujii M, Yoshikumi C, Kawai Y, Shimizu M, Iwaguchi T
Biomedical Research Laboratories, Kureha Chemical Industry, Tokyo, Japan.
J Clin Lab Immunol. 1987 Sep;24(1):33-7.
Spleen and thymus cells from X5563 plasmacytoma-bearing mice treated with PSK (krestin) were analyzed by cell electrophoresis and flow microcytometry. A splenocyte electrophoretic pattern showed that an intermediate mobility peak (IMC), which appeared between the low (B cells) and high (T cells) peaks as the tumor developed, was depressed by the administration of PSK. Thy-1+ cells and asialo-GM1+ (aGM1+) cells decreased with tumor growth, and null cells without a marker of Ig, Thy-1 nor aGM1 increased. However, these changes were corrected by the administration of PSK. As the tumor grew, a thymocyte electrophoretic pattern showed that the incidence of low mobility cells, corresponding to immature cells, decreased, and that of high mobility cells, corresponding to mature cells in the medullary zone, increased. However, PSK suppressed the changes. The tumor did not disappear but life span was prolonged (121%) by the administration of PSK. These results lead to the conclusion that the administration of PSK prevented the changes in surface charge and markers of lymphocytes due to tumor burden, and restored the immunological responsiveness even in the syngeneic system.
对用PSK(云芝多糖K)处理的携带X5563浆细胞瘤的小鼠的脾脏和胸腺细胞进行了细胞电泳和流式细胞术分析。脾细胞电泳图谱显示,随着肿瘤的发展,出现在低迁移率峰(B细胞)和高迁移率峰(T细胞)之间的中间迁移率峰(IMC),在给予PSK后受到抑制。Thy-1+细胞和去唾液酸GM1+(aGM1+)细胞随着肿瘤生长而减少,而无Ig、Thy-1或aGM1标记的裸细胞增加。然而,这些变化通过给予PSK得到纠正。随着肿瘤生长,胸腺细胞电泳图谱显示,对应于未成熟细胞的低迁移率细胞的发生率降低,而对应于髓质区成熟细胞的高迁移率细胞的发生率增加。然而,PSK抑制了这些变化。肿瘤并未消失,但给予PSK可使寿命延长(121%)。这些结果得出结论,给予PSK可防止由于肿瘤负荷导致的淋巴细胞表面电荷和标志物的变化,并即使在同基因系统中也能恢复免疫反应性。